Oragenics 10-Q: Going Concern Doubt, ONP-002 Enrollment Paused, $2.2M Cash Lasts to Year-End
OGEN is trading near its 52-week low of $0.34 (2.1% below the low) on elevated volume (59× avg).
Summary
Oragenics reported a $7.3 million nine-month loss with $2.2 million of cash it says lasts only through December 31, 2026, a paused ONP-002 trial, and a NYSE American compliance plan running to February 2028. The Series H anti-dilution reset to $1.00 leaves 23.9 million potential common shares from warrants alone versus 4.5 million outstanding.
Key Events · Earnings and Guidance · OGEN
-
Going Concern and Thin Cash Runway
Cash and cash equivalents stood at $2.2 million at September 30, 2026, which management says funds planned operations only through December 31, 2026. The nine-month net loss was $7.3 million and operating cash burn was $6.4 million, leaving an accumulated deficit of $234 million.
-
ONP-002 Enrollment Paused on Device Stability
Device stability concerns found in September 2026 paused participant enrollment in the Australian Phase IIa trial, and the pause remains in effect. The IND submission originally projected for end-2026 now faces potentially significant delays; 9 participants and 34 doses had been administered with zero serious adverse events.
-
NYSE American Compliance Plan Accepted
The exchange accepted the company's plan of compliance on November 11, 2026 and granted a plan period through February 25, 2028 to regain compliance with the $4 million and $6 million stockholders' equity standards. Stockholders' equity was $1.09 million at September 30, 2026.
-
Series H Reset Creates 23.9M Share Overhang
The Series H conversion price was lowered to $1.00 per share on March 13, 2026, so the 660,000 Series H warrants now convert into 23,925,000 common shares. Total anti-dilutive securities were 40,713,845 versus 4,511,957 shares outstanding.
Analysis · OGEN · Life Sciences
With $2.2 million of cash, Oragenics says it can fund operations only through December 31, 2026, and the auditor's going-concern doubt is repeated against zero revenue. The lead asset, ONP-002, has been paused since September 2026 on device stability concerns, and the IND filing once targeted for end-2026 now faces potentially significant delays. On the other side, NYSE American accepted a compliance plan on November 11, 2026, giving the company until February 25, 2028 to rebuild stockholders' equity above the $4-6 million thresholds. The equity structure is the other half of the story: the Series H conversion price was reset to $1.00 in March 2026, so the 660,000 Series H warrants now convert into 23,925,000 common shares against just 4,511,957 shares outstanding. Any new financing below $1.00 triggers another reset, which is why the company says the structure itself is making capital raising harder.
How filings like this one have moved
In the 30 days to Nov 12, 2026, 49.5% of the 210 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.54%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, OGEN was trading at $0.33 on NYSE in the Life Sciences sector, with a market capitalization of approximately $1.6M. The 52-week trading range was $0.34 to $1.22. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.